CLGNHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores CollPlant Biotechnologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CLGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Feb 2026 | D. Boral Capital | Downgrade | Hold | — |
| 28 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 5 Aug 2024 | EF Hutton | Initiates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, CollPlant Biotechnologies Ltd. returned −81.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 6% of US stocks
Cheaper than 41% of US stocks
Cheaper than 66% of US stocks
Higher than 7% of US stocks
Higher than 1% of US stocks
Higher than 4% of US stocks
Higher than 97% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CollPlant Biotechnologies Ltd. has a market value of $11.9M and an enterprise value of $6.1M.
Revenue in the twelve months to 31 Mar 2026: $389K. The latest quarter shrank 39.7% year on year.
Net income over the same four quarters: −$13.1M, a −3376.3% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$11.3M, after $25K of capital spending.
Trailing P/E: −4.4×; forward P/E: −10.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CollPlant Biotechnologies Ltd. employs 39 people — $10K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CollPlant Biotechnologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CollPlant Biotechnologies announced that its subsidiary, LightSolver Ltd., secured a paid collaboration with the Israel Ministry of Defense to develop photonic computing technology.
Why it matters — The collaboration is an announcement involving a CollPlant subsidiary and its technology-development work.
CollPlant entered definitive agreements for a $3.7 million private placement, issuing 989,301 ordinary shares or equivalents and warrants to purchase up to 1,483,952 shares. The placement is comprised primarily of existing investors and is intended to accelerate LightSolver’s laser-based supercomputing development.
Why it matters — The transaction adds financing for LightSolver’s development and involves the issuance of shares or equivalents and warrants.
CollPlant announced that its subsidiary, LightSolver, filed a U.S. provisional patent application for an invention expanding the capabilities of its all-optical, laser-based computing platform to advanced scientific and engineering simulations.
Why it matters — The filing adds to LightSolver’s intellectual property portfolio and reflects CollPlant’s photonic computing strategy.
CollPlant Biotechnologies announced its 2026 second quarter financial results and provided a corporate update. The company highlighted a strategic expansion into photonic computing through its acquisition of LightSolver, which diversifies its technology portfolio alongside continued innovations in regenerative medicine.
Why it matters — CLGN watchers would care because the LightSolver acquisition marks a significant strategic diversification for the company beyond its core regenerative medicine business.
CollPlant announced the publication of peer-reviewed joint research conducted by its subsidiary LightSolver with HLRS. The study, published by ACM, demonstrated that LightSolver's LPU architecture projected significantly lower time-to-solution compared to state-of-the-art algorithms running on a GPU for fundamental HPC workloads.
Why it matters — The peer-reviewed validation of LightSolver's photonic computing performance highlights progress in one of CollPlant's key subsidiaries.
Of the 1 analysts covering CollPlant Biotechnologies Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CollPlant Biotechnologies Ltd. 29 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, CollPlant Biotechnologies Ltd. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No analyst covering CollPlant Biotechnologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLGN are extrapolating price history, which says nothing about the business.
CollPlant Biotechnologies Ltd. returned -81.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology". CollPlant Biotechnologies announced that its subsidiary, LightSolver Ltd., secured a paid collaboration with the Israel Ministry of Defense to develop photonic computing technology.
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology. The company’s current portfolio centers on 3D bioprinting for tissues and organs, tissue repair, advanced wound care, and medical aesthetics. Its offerings include bioinks and collagen-based materials designed for regenerative applications, along with products used in soft tissue repair and wound management. CollPlant Biotechnologies also works with partners and collaborators in the broader medical device and biotech ecosystem, supporting applications in orthobiologics, surgical repair, and aesthetic medicine. Headquartered in Rehovot, Israel, CollPlant Biotechnologies Ltd. plays a niche role in the market by combining plant-based biotechnology with collagen innovation for healthcare uses.
CEO Mr. Yehiel Tal · 39 employees · Israel · https://collplant.com
